FDA Approves Genentech's Advanced Lung Cancer Drug
The U.S. Food and Drug Administration on Friday greenlighted Genentech Inc.'s advanced lung cancer drug Alecensa, designed for patients who either weren't helped by or couldn't tolerate Pfizer Inc.'s drug Xalkori....To view the full article, register now.
Already a subscriber? Click here to view full article